ARCHIVES

FDA Approves Gilotrif Tablets in NSCLC, Boehringer Ingelheim’s First Approved Cancer Drug

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

FDA, NCI, CMS Announce Biomarker Initiative; First Project To Validate FDG-PET As Predictor Of Tumor Response In Non-Hodgkin’s Lymphoma.

February 17, 2006

Matted Lymph Nodes Can Predict Survival Rate, Spread of Disease

January 27, 2012

Harkin, Bumpers Concerned Over Centers Funding

May 5, 1989

ONS To Fund 21 Grants In ’94 Deadline Dec. 1

June 11, 1993

New Drug Combination Improves Survival Of Ewing’s Sarcoma, Pediatric Study Finds

February 28, 2003

In Surgery vs Radiotherapy, Outcome Differences Equalize After 15 Years Follow-up

February 22, 2013